Key Points Of WHO Pandemic Agreement
The annual decision-making gathering of the World Health Organization's member states will consider the agreement, which took more than three years to negotiate.
The details of the agreement's central mechanism must still be negotiated by May 2026, after which it can be ratified by countries.
Here are the main points of the agreement, which has 35 articles.
Objective
The objective of the WHO Pandemic Agreement is "strengthening pandemic prevention, preparedness, and response".
Following the glaring inequity and deficiencies exposed in the world's handling of the Covid-19 pandemic, the agreement is guided by the principles of equity, solidarity and transparency.
It says public health decisions in the face of pandemics must be based on "the best available science and evidence".
Respect for the sovereign rights of states is also a key foundation, according to the text.
Prevention and surveillance
Countries must take progressive steps to strengthen their pandemic prevention and surveillance capacities.
Subject to resources, countries are called on to develop, reinforce and implement comprehensive national pandemic prevention plans.
They must bolster the prevention of emerging and re-emerging infectious diseases with early detection and control measures.
This would include things like routine immunisation, managing biological risks in laboratories, preventing antimicrobial resistance, and stopping the transmission of diseases from animals to humans.
Sustainable local production
The text calls for countries to take measures to ensure "more equitable geographical distribution and rapid scale-up of the global production of pandemic-related health products" like vaccines.
It also calls for more "sustainable, timely and equitable access to such products", and for countries to "reduce the potential gap between supply and demand during pandemic emergencies".
Technology transfer
The transfer of technology and know-how needed to produce pandemic-related health products, in particular to developing countries, had been a major sticking point during the negotiations.
Some wealthier countries, notably ones where such products are currently produced, rejected the idea that such transfers should be mandatory.
The agreed-upon text instead calls for transfers to be undertaken on "mutually agreed" terms.
It calls for the use of measures and incentives including licensing agreements and favourable conditions linked to things like financing and regulations to promote technology transfer.
It also aims to promote tech and knowledge transfer to recognised regional or global centres coordinated by the WHO.
Pathogen access, benefit sharing
The heart of the agreement is the proposed Pathogen Access and Benefit-Sharing System (PABS) -- a new platform allowing the swift sharing of pathogen data with pharmaceutical companies, enabling them to start work quickly on pandemic-fighting products.
Under PABS, countries will commit to sharing data rapidly on emerging problematic pathogens, while vaccines and other health products derived from accessing that information would be shared on a more equitable footing.
The text calls for participating manufacturers to make available to the WHO at speed "20 percent of their real-time production" of pandemic-related health products, including "a minimum threshold of 10 percent" in the form of donations, and the rest "reserved at affordable prices" for the UN health agency.
Any company can participate, even if its headquarters are in a country that is not a WHO member state.
The mechanism's details still need to be negotiated and put in an annex by May 2026. To achieve this, an intergovernmental negotiating group must begin meeting before July 15.
Once the annex is finalised and approved, the agreement can be opened for ratification by countries. The agreement enters into force after 60 ratifications.
Supply chain and logistics
In an attempt to smooth out the flaws exposed by Covid-19, a Global Supply Chain and Logistics Network will be set up for equitable, timely and affordable access to pandemic-related health products.
During pandemic emergencies, countries should prioritise sharing pandemic-related health products through the network to ensure equitable distribution based on public health risk and need.
The structure and operational modalities of the network are to be coordinated by the WHO.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Anti-rabies vaccine, immunoglobulin sales pick up as dog bite cases jump
Sanket Koul New Delhi Listen to This Article Anti-rabies vaccine (ARV) and immunoglobulin sales are gradually recovering after the Covid-19 slump, amid a marked increase in dog bite incidence. The rise in sales follows a 76 per cent increase in dog bites, from 2.1 million in 2022 to 3.7 million in 2024. As a result, vaccine makers are preparing to ratchet up production. Bharat Serums and Vaccines (BSV), an arm of Mankind Pharma, told Business Standard that it aims to expand manufacturing by 15-20 per cent, supporting India's mission to eliminate rabies through timely and complete after-exposure treatment. Data from market research firm Pharmarack shows that the combined
&w=3840&q=100)
Business Standard
5 hours ago
- Business Standard
PM Modi asks scientists to focus on R&D, secure patents for new drugs
Prime Minister Narendra Modi on Friday asked scientists and entrepreneurs to focus more on research and development (R&D) and secure patents for new drugs and medical technologies to ensure self-reliance in the pharmaceutical segment. Speaking from the Red Fort on the occasion of India's 79th Independence Day, PM Modi said that this move will ensure that India not only meets its own healthcare needs but also becomes a global hub of medical innovation. The call comes at a time when India has been lagging behind in terms of R&D spending, according to a Department of Pharmaceuticals (DoP) study paper on industry-academia linkages in the segment. It states that while a number of initiatives for industry-academic linkages in India have produced positive research results over the years, due to their sporadic nature, India's share of world researchers has remained at about 2 per cent, compared to 20 per cent in the US and China. 'An analysis of the share in R&D reveals that in India, the government contributes between 75 and 80 per cent, the private sector contributes 20 to 25 per cent, and universities contribute 3 per cent,' the paper added. In comparison, OECD countries see a 69 per cent contribution from private sector companies, followed by universities at 18 per cent, government contribution at 10 per cent, and non-profit organisations at 3 per cent. Commenting on the issues faced by the pharma industry, Kiran Mazumdar-Shaw, executive chairperson of Biocon and Biocon Biologics, told CNBC TV18 that the timeline to take a new molecule from the lab to the market is a very long process, making investments in research and innovation very risky. 'Unless we have very bold regulatory reforms that shorten this lab-to-market journey, we may not see the research investment needed for a country like India,' she added. Calling on the industry to demonstrate India's ability to lead in science, technology, and human welfare, PM Modi also urged the nation to achieve self-reliance in medicines and innovation, highlighting the country's strength as the pharmacy of the world. India currently has approximately 3,000 pharmaceutical businesses with over 10,500 manufacturing facilities, offering around 60,000 generic brands in 60 therapeutic categories. Many Indian pharmaceutical companies are now looking to jump on the generic bandwagon for off-patent molecules, while pressing on plans to develop a biosimilars pipeline post the Covid-19 pandemic. Pharma firms have gone on a generic spree after several blockbuster molecules used in diabetes medications, such as empagliflozin and dapagliflozin, went off patent in the last two years. Major blockbuster molecules that have seen several generic launches in this timeframe include empagliflozin and dapagliflozin, used in diabetes medications, which saw the prices of these drugs fall by 85 per cent in the Indian market. Similarly, companies such as Sun Pharma, Torrent, Lupin, Glenmark, and Dr Reddy's are also working on generic versions of weight loss drugs based on the blockbuster molecule semaglutide, which is expected to go off patent by March 2026. According to the DoP's study paper, more than 300 drug patents in different categories and geographies will be expiring every year during the patent cliff period of 2022 to 2032. 'The patent cliff will provide an opportunity for Indian generic companies to enter the US and other regulated markets and produce more affordable versions of those medications,' the paper added. PM flags obesity crisis in I-Day speech, calls for less oil intake PM Modi on Friday expressed concerns over obesity becoming a future crisis for India, asking people to cut down consumption of cooking oil by at least 10 per cent. India is currently projected to have the third-highest population of overweight or obese people globally, after the United States of America (USA) and China. Asking every family to take the concern seriously, the Prime Minister resolved that the country must protect itself from obesity. 'While many steps will have to be taken, I have made one small suggestion that every family should resolve that when cooking oil comes into the house, it should be 10 per cent less than usual, and its use should also be 10 per cent less. By doing so, we shall make our contribution towards winning the fight against obesity,' he stated from the ramparts of the Red Fort. According to the National Family Health Survey-5 (2019-21), 24 per cent of women and 23 per cent of men in India are overweight or obese, a sharp rise from 20.7 per cent and 18.6 per cent recorded in the NFHS-4 (2015-16), respectively. A recent Lancet study had also predicted that nearly one-third of the country's population, amounting to 218 million men and 231 million women, will be obese by 2050.
&w=3840&q=100)
Business Standard
7 hours ago
- Business Standard
Kerala's 'Cancer free Kannapuram' programme gets recognised by WHO
The Cancer-Free Kannapuram initiative, launched in 2016 in Kerala's Kannapuram gram panchayat, has been officially recognised by the World Health Organization (WHO) for its remarkable impact on early detection and control of cancer. This model, rooted in community participation and effective local leadership, has emerged as a replicable template for similar efforts worldwide. What is the Kannapuram model? The model integrates over a decade of community engagement, mobilising local stakeholders under the Gram Panchayat's leadership alongside technical support from a Comprehensive Cancer Care Centre (CCCC). Phase 1: Sensitisation workshops were held, uniting local self-government representatives, primary health staff, and self-help groups with doctors, to raise awareness and form grassroots committees. A comprehensive door-to-door survey followed, identifying high-risk individuals while also exposing deep-rooted fear and misinformation about cancer. Phase 2: This phase included distributing information, education, and communication (IEC) materials, hosting health exhibitions at community events, organising 'winners meets' where survivors shared experiences to reduce fear. It also featured literary competitions, panel discussions on diet and cancer prevention, kitchen garden promotion, and school campaigns on cancer and tobacco with Parent-Teacher Association support. Phase 3: The gram panchayat launched a breast cancer screening project, starting with a single-day registration drive covering 3,800 homes. A 10-day mega camp followed, screening healthy women over 30 with no breast cancer history. Trained female technicians examined 200–500 women daily. Participants received pamphlets and training on self-examination. Women with positive results were counselled and referred to the CCCC for further tests, supported by a dedicated team that coordinated appointments, travel, and follow-ups, ensuring smooth access to care. Impressive outcomes A staggering 96 per cent of eligible women participated in the screening camp, and the detection rate was 0.96 per 1,000. More tests were required for 6.2 per cent of women, according to the positivity in the screening test and findings of the CBE. The majority of them, making up 84 per cent, had no symptoms. Further assessment participation rate either at the CCCC or elsewhere was 66.5 per cent due to continuous intervention and motivation by the volunteers despite having no symptoms. Why the model succeeded Continuous awareness drives, women-led leadership, and community trust were key to the programme's success. As noted in the WHO South-East Asia Journal of Public Health paper on the initiative, 'In our study, the continuous awareness campaigns led by female members, acceptable and cost-free screening methods, well-organised screening camps with female providers, and the geographically accessible campsite led to increased screening participation. The involvement of the community helped to overcome most of the barriers at large, address the possible mistrust between the health system and the public, and sustain the interventions to achieve the goal.' Kannapuram gram panchayat president Rethi K told Deccan Herald that the initiative's success lay in removing the stigma around cancer and ensuring regular screening camps. "We initiated the programme after it came to our notice that many people in the panchayat were suffering from cancer, especially women, and many were reluctant to rule out suspicions owing to fear and stigma. The awareness camps really helped in addressing these issues. As a result, 96 percent of women above the age of 30 could be screened," she said. The Kannapuram model exemplifies how community-driven health initiatives can transform cancer screening and outcomes. It aligns with the WHO's Global Breast Cancer Initiative, which identifies three key pillars for reducing breast cancer mortality: health promotion and early detection, timely diagnosis, and comprehensive cancer management.
